Lonza Group Ltd. and Octane Biotech Inc. in Canada, a regenerative medicine company, have formed an exclusive technology evaluation of the Octane Cocoon cell production platform for personalized cell therapy manufacturing with the goal of a global deployment. The Octane Cocoon has the potential to enable the automated manufacturing of patient-specific cell therapies for traceability and scale-up. Under the terms of the agreement, Lonza will evaluate the Octane Cocoon platform for autologous cell therapy products.

Octane Cocoon is a patient-scale cell therapy system that forms the core of a series of cell and tissue therapy production systems. The platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation in a closed, single-use disposable cassette.

Source: Octane Biotech